In what has been the busiest week for European biotechnology stocks for several years, investors flooded back into the sector in a series of transactions in Sweden, Germany and Belgium. Several more are in the offing, some of which are already fully guaranteed. (BioWorld International)

Biovitrum AB has taken a significant step in its goal to become a fully integrated, specialty pharmaceutical firm focused on niche indications, with an SEK3.656 billion (US$533.1 million) cash-and-shares acquisition of Swedish Orphan International AB. (BioWorld International)